CIBC World Market
MBRX icon

CIBC World Market’s Moleculin Biotech MBRX Stock Holding History

CIBC World Market’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4
Closed -$170K – 1191
2018
Q4 		$170K Buy
4
+2
+100% +$115K ﹤0.01% 1020
2018
Q3 		$143K Hold
2
– – ﹤0.01% 1084
2018
Q2 		$170K Buy
2
+1
+100% +$81.9K ﹤0.01% 1090
2018
Q1 		$117K Buy
+1
New +$86.5K ﹤0.01% 1118

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CVI Holdings
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Whitegate Investment Counselors
Whitegate Investment Counselors Concord, New Hampshire $343M AUM 8.81% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

CIBC World Market's MBRX Position: Q1 2019 in Review

CIBC World Market sold out of Moleculin Biotech (MBRX) in Q1 2019, closing a stake of 4 shares — an estimated $170K sold.

CIBC World Market first reported a position in MBRX in Q1 2018 and held it in 4 quarters. The position peaked at $170K in Q4 2018. 11 funds tracked by Wall St. Rank hold MBRX as of Q1 2019.

  • CIBC World Market reported no remaining Moleculin Biotech position as of Q1 2019 after selling out during the quarter.
  • CIBC World Market sold 4 Moleculin Biotech shares in Q1 2019, an estimated $170K.
  • CIBC World Market first reported a position in Moleculin Biotech in Q1 2018 and held it in 4 quarters.
  • CIBC World Market's Moleculin Biotech position peaked at $170K in Q4 2018.
  • 11 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2019.

Based on CIBC World Market's 13F filing for Q1 2019, filed 9 May 2019.